Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Parkinson's Disease – Pipeline Review, H2 2016, provides an overview of the Parkinson's Disease (Central Nervous System) pipeline landscape.

Parkinson's disease is a neurodegenerative disorder characterized by movement dysfunctions. It causes involuntary shaking, stiffness and impaired locomotory functions. Age, genetic factors, head trauma, environmental factors, hormonal changes, etc are predisposing factors for Parkinson’s disease. Parkinson’s disease results in abnormal functioning or death of neurons. The neurons are responsible for the synthesis of neurotransmitter dopamine which is further responsible for the transmission of signals. The effect on the neurons blocks effective neurotransmission and may lead to eventual decline in movement and coordination.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Parkinson's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 30, 37, 5, 173, 42 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 1, 1, 50, 15 and 1 molecules, respectively.

Parkinson's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson's Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Parkinson's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Parkinson's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Parkinson's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson's Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Parkinson's Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Parkinson's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

2-BBB Medicines BV
4P Therapeutics LLC
AbbVie Inc
AC Immune SA
Acelot Inc
Acorda Therapeutics Inc
Adamas Pharmaceuticals Inc
Addex Therapeutics Ltd
Advinus Therapeutics Ltd
Aeolus Pharmaceuticals Inc
AFFiRiS AG
Amabiotics SAS
Amarantus Bioscience Holdings Inc
American Gene Technologies International Inc
Anavex Life Sciences Corp
Angita BV
Antoxis Ltd
Aoxing Pharmaceutical Company Inc
APeT Holding BV
ApoPharma Inc
Aposense Ltd
Araclon Biotech SL
ArmaGen Inc
Arrien Pharmaceuticals LLC
AstraZeneca Plc
AudioCure Pharma GmbH
Berg LLC
Bial - Portela & Ca SA
Bio-Modeling Systems SAS
BioArtic AB
Biogen Inc
BioHealthonomics Inc
Biopharm GmbH
Biotie Therapies Corp
BrainStorm Cell Therapeutics Inc
Calico LLC
Cantabio Pharmaceuticals Inc
Cardax Inc
Carna Biosciences Inc
Cell Cure Neurosciences Ltd
Cellceutix Corp
CHA Bio & Diostech Co Ltd
Chipscreen Biosciences Ltd
Clera Inc
Clevexel Pharma SA
Contera Pharma ApS
ContraVir Pharmaceuticals Inc
Corium International Inc
Curemark LLC
Daewoong Pharmaceutical Co Ltd
Denali Therapeutics Inc
Depomed Inc
DermaXon LLC
Diffusion Pharmaceuticals Inc
Dizlin Medical Design AB
Domain Therapeutics SA
Edison Pharmaceuticals Inc
Eli Lilly and Company
Ensemble Therapeutics Corp
Fabre-Kramer Pharmaceuticals Inc
FPRT Bio Inc
Genecode AS
Generon (Shanghai) Corp Ltd
Genervon Biopharmaceuticals LLC
GenKyoTex SA
Genmab A/S
Genosco Inc
Genzyme Corp
H. Lundbeck A/S
Harbor Therapeutics Inc
Heptares Therapeutics Ltd
Herantis Pharma Plc
Hisamitsu Pharmaceutical Co Inc
Horizon Pharma Plc
Huons Co Ltd
ICB International Inc
Immungenetics AG
Impel NeuroPharma Inc
Intec Pharma ltd
Integrative Research Laboratories Sweden AB
InterMed Discovery GmbH
International Stem Cell Corp
Io Therapeutics Inc
Iproteos SL
Jeil Pharmaceutical Co Ltd
Kainos Medicine Inc
Khondrion BV
KineMed Inc
Kissei Pharmaceutical Co Ltd
Kyowa Hakko Kirin Co Ltd
Lead Discovery Center GmbH
Living Cell Technologies Ltd
Longevity Biotech Inc
Luye Pharma Group Ltd
Lysosomal Therapeutics Inc
M et P Pharma AG
M's Science Corp
M3 Biotechnology Inc
MedGenesis Therapeutix Inc
MedImmune LLC
MeiraGTx Ltd
Merck & Co Inc
Metabolic Solutions Development Company LLC
Minerva Neurosciences Inc
Mission Therapeutics Ltd
Mitochon Pharmaceuticals Inc
MitoDys Therapeutics Ltd
Motac Neuroscience Ltd
Netherlands Translational Research Center BV
Neuralstem Inc
Neuraltus Pharmaceuticals Inc
Neuren Pharmaceuticals Ltd
NeuroDerm Ltd
NeuroNascent Inc
NeurOp Inc
Neuropore Therapies Inc
New World Laboratories Inc
Newron Pharmaceuticals SpA
nLife Therapeutics SL
NLS Pharma Group
Novartis AG
Novo Nordisk A/S
NsGene A/S
Omeros Corp
Oncodesign SA
Ono Pharmaceutical Co Ltd
OPKO Health Inc
Orion Oyj
Oryzon Genomics SA
Oxford BioMedica Plc
ParkCell AB
Peptron Inc
Pfizer Inc
Pharma Two B Ltd
PharmatrophiX Inc
Pharmaxis Ltd
Pharmicell Co Ltd
Pharnext SA
Phenomenome Discoveries Inc
Plex Pharmaceuticals Inc
Prana Biotechnology Ltd
Prexton Therapeutics SA
Primary Peptides Inc
Proclara Biosciences Inc
Promentis Pharmaceuticals Inc
Promius Pharma LLC
Proteostasis Therapeutics Inc
Prothena Corp Plc
QR Pharma Inc
reMYND NV
Retrotope Inc
Sage Therapeutics Inc
Saje Pharma LLC
SanBio Inc
Saneron CCEL Therapeutics Inc
Saniona AB
Sellas Inc
Serina Therapeutics Inc
Shire Plc
Sigma-Tau SpA
SignPath Pharma Inc
Signum Biosciences Inc
SK Biopharmaceuticals Co Ltd
STATegics Inc
Stelic Institute & Co Inc
Sun Pharma Advanced Research Company Ltd
Sunovion Pharmaceuticals Inc
Synthonics Inc
Takara Bio Inc
Takeda Pharmaceutical Company Ltd
TauRx Therapeutics Ltd
TechnoPhage SA
Teikoku Pharma USA Inc
Teva Pharmaceutical Industries Ltd
Titan Pharmaceuticals Inc
Trevena Inc
TyrNovo Ltd
UniQure NV
Vanton Research Laboratory LLC
Varinel Inc
VistaGen Therapeutics Inc
VivaCell Biotechnology Espana SL
Voyager Therapeutics Inc
vTv Therapeutics Inc
Wellstat Therapeutics Corp